{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T10:14:11Z","timestamp":1783764851502,"version":"3.55.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["GeroScience"],"DOI":"10.1007\/s11357-025-02050-5","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T22:15:31Z","timestamp":1768256131000},"page":"3755-3787","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Adoptive T-cell therapies for persistent COVID-19 in immunocompromised patients: Comparison of IFN-\u03b3 virus-specific T-cell therapy and CD45RA+ T-cell depleted donor lymphocyte infusion"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4930-7049","authenticated-orcid":false,"given":"L\u00e1szl\u00f3","family":"Gopcsa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5898-368X","authenticated-orcid":false,"given":"Borisz Rab\u00e1n","family":"Petrik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1775-1356","authenticated-orcid":false,"given":"B\u00e1lint Gergely","family":"Szab\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4682-5628","authenticated-orcid":false,"given":"Marienn","family":"R\u00e9ti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8368-9784","authenticated-orcid":false,"given":"Hajnalka","family":"Andrikovics","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2187-4666","authenticated-orcid":false,"given":"Ilona","family":"Bobek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8539-5897","authenticated-orcid":false,"given":"Gabriella","family":"Bek\u0151","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Bogy\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4285-7518","authenticated-orcid":false,"given":"Andrea","family":"Cegl\u00e9di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Dobos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Giba-Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orsolya","family":"Kis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7276-7639","authenticated-orcid":false,"given":"Botond","family":"Lakatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00f3ra","family":"Mathi\u00e1sz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00f3ra","family":"Meggyesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gottfried","family":"Miskolczi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mi","family":"N\u00e9meth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7721-6828","authenticated-orcid":false,"given":"J\u00e1nos","family":"Sink\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4092-6073","authenticated-orcid":false,"given":"Anik\u00f3","family":"Szilv\u00e1si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e1nos","family":"Szl\u00e1vik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6736-3493","authenticated-orcid":false,"given":"Szabolcs","family":"Tasn\u00e1dy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"V\u00e1rnai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9664-9067","authenticated-orcid":false,"given":"P\u00e9ter","family":"Rem\u00e9nyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3581-113X","authenticated-orcid":false,"given":"Istv\u00e1n","family":"V\u00e1lyi-Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"2050_CR1","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41586-022-05522-2","volume":"613","author":"W Msemburi","year":"2023","unstructured":"Msemburi W, Karlinsky A, Knutson V, Aleshin-Guendel S, Chatterji S, Wakefield J. The WHO estimates of excess mortality associated with the COVID-19 pandemic. Nature. 2023;613:130\u20137. https:\/\/doi.org\/10.1038\/s41586-022-05522-2.","journal-title":"Nature"},{"key":"2050_CR2","unstructured":"WHO warns of slowing global health gains in new statistics report [WHO Web site]. 2025. https:\/\/www.who.int\/news\/item\/15-05-2025-who-warns-of-slowing-global-health-gains-in-new-statistics-report. Accessed 15 May 2025."},{"key":"2050_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1985","volume":"369","author":"AB Docherty","year":"2020","unstructured":"Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study. BMJ. 2020;369:m1985. https:\/\/doi.org\/10.1136\/bmj.m1985.","journal-title":"BMJ"},{"key":"2050_CR4","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1038\/s41598-024-84379-z","volume":"15","author":"L Wemh\u00f6ner","year":"2025","unstructured":"Wemh\u00f6ner L, Brandts C, Dinse H, Skoda E-M, Jansen S, Teufel M, et al. Consequences of COVID-19 for geriatric patients during a pandemic. Sci Rep. 2025;15:3136. https:\/\/doi.org\/10.1038\/s41598-024-84379-z.","journal-title":"Sci Rep"},{"key":"2050_CR5","unstructured":"COVID-19 -Global situation [WHO Web site] 2025. https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2025-DON572. Accessed 28 May 2025."},{"key":"2050_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-024-00633-5","volume":"4","author":"I Bartha","year":"2024","unstructured":"Bartha I, Maher C, Lavrenko V, Chen Y-P, Tao Q, di Iulio J, et al. Morbidity of SARS-CoV-2 in the evolution to endemicity and in comparison with influenza. Commun Med. 2024;4:244. https:\/\/doi.org\/10.1038\/s43856-024-00633-5.","journal-title":"Commun Med"},{"key":"2050_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/covid5010011","volume":"5","author":"G Lippi","year":"2025","unstructured":"Lippi G, Sanchis-Gomar F. Mortality of post-COVID-19 condition: 2025 update. COVID. 2025;5:11. https:\/\/doi.org\/10.3390\/covid5010011.","journal-title":"COVID"},{"key":"2050_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journalpmed.1004086","volume":"20","author":"L Turtle","year":"2023","unstructured":"Turtle L, Thorpe M, Drake TM, Swets M, Palmieri C, Russell CD, et al. Outcome of COVID-19 in hospitalised immunocompromised patients: an analysis of the WHO ISARIC CCP-UK prospective cohort study. PLoS Med. 2023;20:e1004086. https:\/\/doi.org\/10.1371\/journalpmed.1004086.","journal-title":"PLoS Med"},{"key":"2050_CR9","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s40121-025-01124-3","volume":"14","author":"P Loubet","year":"2025","unstructured":"Loubet P, Benotmane I, Fourati S, Malard F, Vuotto F, Blanchard E, et al. Avouac. Risk of severe COVID-19 in four immunocompromised populations: a french expert perspective. Infect Dis Ther. 2025;14:671\u2013733. https:\/\/doi.org\/10.1007\/s40121-025-01124-3.","journal-title":"Infect Dis Ther"},{"key":"2050_CR10","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1056\/NEJMc2031364","volume":"383","author":"B Choi","year":"2020","unstructured":"Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med. 2020;383:2291\u20133. https:\/\/doi.org\/10.1056\/NEJMc2031364.","journal-title":"N Engl J Med"},{"key":"2050_CR11","doi-asserted-by":"publisher","unstructured":"Li Y, Choudhary MC, Regan J, Boucau J, Nathan A, Speidel T, et al. SARS-CoV-2 viral clearance and evolution varies by extent of immunodeficiency. medRXiv. 2023:23293441. https:\/\/doi.org\/10.1101\/2023.07.31.23293441.","DOI":"10.1101\/2023.07.31.23293441"},{"key":"2050_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-024-02378-y","volume":"21","author":"S Feng","year":"2024","unstructured":"Feng S, Reid GE, Clark NM, Harrington A, Uprichard SL, Baker SC. Evidence of SARS-CoV-2 convergent evolution in immunosuppressed patients treated with antiviral therapies. Virol J. 2024;21:105. https:\/\/doi.org\/10.1186\/s12985-024-02378-y.","journal-title":"Virol J"},{"key":"2050_CR13","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.00110-24","volume":"15","author":"AD Marques","year":"2024","unstructured":"Marques AD, Graham-Wooten J, Fitzgerald AS, Leonard AS, Cook EJ, Everett JK, et al. SARS-CoV-2 evolution during prolonged infection in immunocompromised patients. MBio. 2024;15:e00110-24. https:\/\/doi.org\/10.1128\/mbio.00110-24.","journal-title":"MBio"},{"key":"2050_CR14","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.7326\/ANNALS-24-00464","volume":"177","author":"RM Gulick","year":"2024","unstructured":"Gulick RM, Pau AK, Daar E, Evans L, Gandhi RT, Tebas P, et al. National Institutes of Health COVID-19 treatment guidelines panel: perspectives and lessons learned. Ann Intern Med. 2024;177:1547\u201357. https:\/\/doi.org\/10.7326\/ANNALS-24-00464.","journal-title":"Ann Intern Med"},{"key":"2050_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29082","volume":"95","author":"JM Caso","year":"2023","unstructured":"Caso JM, Fern\u00e1ndez-Ruiz M, L\u00f3pez-Medrano F, Caro-Teller JM, Lizasoain M, San-Juan R, et al. Nirmatrelvir\/ritonavir for the treatment of immunocompromised adult patients with early\u2010stage symptomatic COVID\u201019: a real\u2010life experience. J Med Virol. 2023;95:e29082.","journal-title":"J Med Virol"},{"key":"2050_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02649-9","author":"S Cesaro","year":"2025","unstructured":"Cesaro S, Ljungman P, Mikulska M, Hirsch HH, Navarro D, Cordonnier C, et al. Post-pandemic recommendations for the management of COVID-19 in patients with haematological malignancies or undergoing cellular therapy, from the European Conference on Infections in Leukaemia (ECIL-10). Leukemia. 2025. https:\/\/doi.org\/10.1038\/s41375-025-02649-9.","journal-title":"Leukemia"},{"key":"2050_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.751869","volume":"12","author":"N Kim","year":"2021","unstructured":"Kim N, Lee J-M, Oh E-J, Jekarl DW, Lee D-G, Im K-I, et al. Off-the-shelf partial HLA matching SARS-CoV-2 antigen specific T cell therapy: a new possibility for COVID-19 treatment. Front Immunol. 2021;12:751869. https:\/\/doi.org\/10.3389\/fimmu.2021.751869.","journal-title":"Front Immunol"},{"key":"2050_CR18","doi-asserted-by":"publisher","unstructured":"Guerreiro M, Aguilar\u2010Gallardo C, Montoro J, Franc\u00e9s\u2010G\u00f3mez C, Latorre V, Luna I, Planelles D, Carrasco MP, G\u00f3mez MD, Gonz\u00e1lez-Barber\u00e1 EM, Aguardo C, Sempere A, Solves P, G\u00f3mez-Segu\u00ed I, Balaguer-Rosello A, Louro A, Perla A, Larrea L, Sanz J, Arbona C, de la Rubia, Geller R, Sanz M\u00c1, Sanz G, Pi\u00f1ana. Adoptive Transfer of Ex Vivo Expanded SARS\u2010CoV\u20102\u2010specific Cytotoxic Lymphocytes: A Viable Strategy for COVID\u201019 Immunosuppressed Patients? Transpl Infect Dis. 2021;23: e13602. https:\/\/doi.org\/10.1111\/tid.13602.","DOI":"10.1111\/tid.13602"},{"key":"2050_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-94654-y","volume":"11","author":"R Sivapalan","year":"2021","unstructured":"Sivapalan R, Liu J, Chakraborty K, Arthofer E, Choudhry M, Barie PS, et al. Virus induced lymphocytes (VIL) as a novel viral antigen-specific T cell therapy for COVID-19 and potential future pandemics. Sci Rep. 2021;11:15295. https:\/\/doi.org\/10.1038\/s41598-021-94654-y.","journal-title":"Sci Rep"},{"key":"2050_CR20","doi-asserted-by":"publisher","first-page":"572.e1","DOI":"10.1016\/j.jtct.2023.06.001","volume":"29","author":"R Mora-Buch","year":"2023","unstructured":"Mora-Buch R, Tom\u00e1s-Mar\u00edn T, Enrich E, Ant\u00f3n-Iborra M, Martorell L, Valdivia E, et al. Virus-specific T cells from cryopreserved blood during an emergent virus outbreak for a potential off-the-shelf therapy. Transplant Cell Ther. 2023;29:572.e1-572.e13. https:\/\/doi.org\/10.1016\/j.jtct.2023.06.001.","journal-title":"Transplant Cell Ther"},{"key":"2050_CR21","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jcyt.2022.12.001","volume":"25","author":"K Al-Akioui-Sanz","year":"2023","unstructured":"Al-Akioui-Sanz K, Pascual-Miguel B, D\u00edaz-Almir\u00f3n M, Mestre-Dur\u00e1n C, Navarro-Zapata A, Clares-Villa L, et al. Donor selection for adoptive cell therapy with CD45RA\u2212 memory T cells for patients with coronavirus disease 2019, and dexamethasone and interleukin-15 effects on the phenotype, proliferation and interferon gamma release. Cytotherapy. 2023;25:330\u201340. https:\/\/doi.org\/10.1016\/j.jcyt.2022.12.001.","journal-title":"Cytotherapy"},{"key":"2050_CR22","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008825","author":"A Papadopoulou","year":"2014","unstructured":"Papadopoulou A, Gerdemann U, Katari UL, Tzannou I, Liu H, Martinez C, et al. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014. https:\/\/doi.org\/10.1126\/scitranslmed.3008825.","journal-title":"Sci Transl Med"},{"key":"2050_CR23","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/978-3-319-22834-1_15","volume":"391","author":"S Gottschalk","year":"2015","unstructured":"Gottschalk S, Rooney CM. Adoptive T cell immunotherapy. Curr Top Microbiol Immunol. 2015;391:427\u201354. https:\/\/doi.org\/10.1007\/978-3-319-22834-1_15.","journal-title":"Curr Top Microbiol Immunol"},{"key":"2050_CR24","doi-asserted-by":"publisher","unstructured":"Jiang W, Clancy LE, Avdic S, Sutrave G, Street J, Simms R, et al. Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant. Blood Adv. 2022(17). https:\/\/doi.org\/10.1182\/bloodadvances.2022007103.","DOI":"10.1182\/bloodadvances.2022007103"},{"key":"2050_CR25","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jtct.2023.03.031","volume":"29","author":"RJ O\u2019Reilly","year":"2023","unstructured":"O\u2019Reilly RJ. T-cells: third party parity for viral infections. Transplant Cell Ther. 2023;29:285\u20136. https:\/\/doi.org\/10.1016\/j.jtct.2023.03.031.","journal-title":"Transplant Cell Ther"},{"key":"2050_CR26","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1200\/JCO.2017.73.0655","volume":"35","author":"I Tzannou","year":"2017","unstructured":"Tzannou I, Papadopoulou A, Naik S, Leung K, Martinez CA, Ramos CA, et al. Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2017;35:3547\u201357. https:\/\/doi.org\/10.1200\/JCO.2017.73.0655.","journal-title":"J Clin Oncol"},{"key":"2050_CR27","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1158\/1078-0432.CCR-22-2415","volume":"29","author":"T Pfeiffer","year":"2023","unstructured":"Pfeiffer T, Tzannou I, Wu M, Ramos C, Sasa G, Martinez C, et al. Posoleucel, an allogeneic, off-the-shelf multivirus-specific T-cell therapy, for the treatment of refractory viral infections in the post-HCT setting. Clin Cancer Res. 2023;29:324\u201330. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2415.","journal-title":"Clin Cancer Res"},{"key":"2050_CR28","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1182\/bloodadvances.2023011562","volume":"8","author":"SS Dadwal","year":"2024","unstructured":"Dadwal SS, Bansal R, Schuster MW, Yared JA, Myers GD, Matzko M, et al. Final outcomes from a phase 2 trial of posoleucel in allogeneic hematopoietic cell transplant recipient. Blood Adv. 2024;8:4740\u201350. https:\/\/doi.org\/10.1182\/bloodadvances.2023011562.","journal-title":"Blood Adv"},{"issue":"Supplement_1","key":"2050_CR29","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1093\/jpids\/piad077","volume":"13","author":"A Green","year":"2024","unstructured":"Green A, Rubinstein JD, Grimley M, Pfeiffer T. Virus-specific T cells for the treatment of systemic infections following allogeneic hematopoietic cell and solid organ transplantation. J Pediatr Infect Dis Soc. 2024;13(Supplement_1):S49-57. https:\/\/doi.org\/10.1093\/jpids\/piad077.","journal-title":"J Pediatr Infect Dis Soc"},{"key":"2050_CR30","doi-asserted-by":"publisher","unstructured":"Gopcsa L, R\u00e9ti M, Andrikovics H, Bobek I, Bek\u0151 G, Bogy\u00f3 J, Cegl\u00e9di A, Dobos K, Giba-Kiss Laura, Jankovics I, Kis O, Lakatos B, Mathi\u00e1sz D, Meggyesi N, Miskolczi G, N\u00e9meth N, Paksi M, Riczu A, Sink\u00f3 J, Szab\u00f3 B, Szilv\u00e1si A, Szl\u00e1vik J, Szabolcs Tasn\u00e1dy Sz, Rem\u00e9nyi P, V\u00e1lyi-Nagy I. Effective virus-specific T-cell therapy for high-risk SARS-CoV-2 infections in hematopoietic stem cell transplant recipients: initial case studies and literature review. Geroscience. 2024;46: 1083\u20131106. https:\/\/doi.org\/10.1007\/s11357-023-00858-7.","DOI":"10.1007\/s11357-023-00858-7"},{"key":"2050_CR31","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jcyt.2024.05.014","volume":"26","author":"MS-F Seng","year":"2024","unstructured":"Seng MS-F, Ng KP, Soh TG, Tan TT, Chan M, Maiwald M, et al. A phase I\/II study of adoptive SARS-CoV-2-specific T cells in immunocompromised hosts with or at risk of severe COVID-19 infection. Cytotherapy. 2024;26:1170\u20138. https:\/\/doi.org\/10.1016\/j.jcyt.2024.05.014.","journal-title":"Cytotherapy"},{"key":"2050_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.12.435","volume":"26","author":"AC Talleur","year":"2020","unstructured":"Talleur AC, Li Y, Akel S, Sharma A, Qudeimat A, Srinivasan A, et al. Haploidentical CD45RA-negative donor lymphocyte infusions are feasible, safe and associated with clinical benefit. Biol Blood Marrow Transplant. 2020;26:S268. https:\/\/doi.org\/10.1016\/j.bbmt.2019.12.435.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2050_CR33","doi-asserted-by":"publisher","unstructured":"Gasior Kabat M, Bueno D, Sisinni L, De Paz R, Mozo Y, Perona R, Arias-Salgado EG, Rosich B, Marcos A, Romero AB, Constanzo, Jim\u00e9nez-Yuste V, P\u00e9rez-Mart\u00ednez A. Selective T-Cell Depletion Targeting CD45RA as a Novel Approach for HLA-Mismatched Hematopoietic Stem Cell Transplantation in Pediatric Nonmalignant Hematological Diseases. Int J Hematol. 2021;114: 116\u2013123. https:\/\/doi.org\/10.1007\/s12185-021-03138-2.","DOI":"10.1007\/s12185-021-03138-2"},{"key":"2050_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1009143","volume":"12","author":"S Naik","year":"2023","unstructured":"Naik S, Triplett BM. Selective depletion of na\u00efve T cells by targeting CD45RA. Front Oncol. 2023;12:1009143. https:\/\/doi.org\/10.3389\/fonc.2022.1009143.","journal-title":"Front Oncol"},{"key":"2050_CR35","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.bbmt.2014.01.032","volume":"20","author":"M Bleakley","year":"2014","unstructured":"Bleakley M, Heimfeld S, Jones LA, Turtle C, Krause D, Riddell SR, et al. Engineering human peripheral blood stem cell grafts that are depleted of na\u00efve T cells and retain functional pathogen-specific memory T cells. Biol Blood Marrow Transplant. 2014;20:705\u201316. https:\/\/doi.org\/10.1016\/j.bbmt.2014.01.032.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2050_CR36","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1172\/JCI81229","volume":"125","author":"M Bleakley","year":"2015","unstructured":"Bleakley M, Heimfeld S, Loeb KR, Jones LA, Chaney C, Seropian S, et al. Outcomes of acute leukemia patients transplanted with naive T cell\u2013depleted stem cell grafts. J Clin Invest. 2015;125:2677\u201389. https:\/\/doi.org\/10.1172\/JCI81229.","journal-title":"J Clin Invest"},{"key":"2050_CR37","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1200\/JCO.21.01755","volume":"40","author":"M Bleakley","year":"2022","unstructured":"Bleakley M, Sehgal A, Seropian S, Biernacki MA, Krakow EF, Dahlberg A, et al. Naive T-cell depletion to prevent chronic graft-versus-host disease. J Clin Oncol. 2022;40:1174\u201385. https:\/\/doi.org\/10.1200\/JCO.21.01755.","journal-title":"J Clin Oncol"},{"key":"2050_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12081853","volume":"12","author":"S Braidotti","year":"2024","unstructured":"Braidotti S, Granzotto M, Curci D, Kotnik BF, Maximova N. Advancing allogeneic hematopoietic stem cell transplantation outcomes through immunotherapy: a comprehensive review of optimizing non-CAR donor T-lymphocyte infusion strategies. Biomedicines. 2024;12:1853. https:\/\/doi.org\/10.3390\/biomedicines12081853.","journal-title":"Biomedicines"},{"key":"2050_CR39","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.1016\/j.bbmt.2019.01.023","volume":"25","author":"L Shelikhova","year":"2019","unstructured":"Shelikhova L, Ilushina M, Shekhovtsova Z, Shasheleva D, Khismatullina R, Kurnikova E, et al. \u03b1\u03b2 T cell-depleted haploidentical hematopoietic stem cell transplantation without antithymocyte globulin in children with chemorefractory acute myelogenous leukemia. Biol Blood Marrow Transplant. 2019;25:e179\u201382. https:\/\/doi.org\/10.1016\/j.bbmt.2019.01.023.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2050_CR40","doi-asserted-by":"publisher","unstructured":"Maung KK, Chen BJ, Barak I, Li Z, Rizzieri DA, Gasparetto C, Sullivan KM, Long GD, Engemann AM, Waters-Pick B, Nichols KR, Lopez R, Kang Y, Sarantopoulos, Sung AD, Chao NJ, Horwitz. Phase I Dose Escalation Study of Naive T-Cell Depleted Donor Lymphocyte Infusion Following Allogeneic Stem Cell Transplantation. Bone Marrow Transplant. 2021; 56: 137\u201343. https:\/\/doi.org\/10.1038\/s41409-020-0991-5.","DOI":"10.1038\/s41409-020-0991-5"},{"key":"2050_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.620730","volume":"9","author":"C Ferreras","year":"2021","unstructured":"Ferreras C, Pascual-Miguel B, Mestre-Dur\u00e1n C, Navaro-Zapata A, Clares-Villa L, Mart\u00edn-Cost\u00e1zar C, et al. SARS-CoV-2-specific memory T lymphocytes from COVID-19 convalescent donors: identification, biobanking, and large-scale production for adoptive cell therapy. Front Cell Dev Biol. 2021;9:620730.","journal-title":"Front Cell Dev Biol"},{"key":"2050_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05625-7","volume":"22","author":"I Garc\u00eda-Garc\u00eda","year":"2021","unstructured":"Garc\u00eda-Garc\u00eda I, Guerra-Garc\u00eda P, Ferreras C, Borobia AM, Carcas AJ, Queiruga-Parada J, et al. A phase I\/II dose-escalation multi-center study to evaluate the safety of infusion of natural killer cells or memory T cells as adoptive therapy in coronavirus pneumonia and\/or lymphopenia: RELEASE study protocol. Trials. 2021;22:674.","journal-title":"Trials"},{"key":"2050_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101086","volume":"39","author":"A P\u00e9rez-Mart\u00ednez","year":"2021","unstructured":"P\u00e9rez-Mart\u00ednez A, Mora-Rillo M, Ferreras C, Guerra-Garc\u00eda P, Pascual-Miguel B, Mestre-Dur\u00e1n C, et al. Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE). EClinicalMedicine. 2021;39:101086.","journal-title":"EClinicalMedicine"},{"key":"2050_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1083215","volume":"10","author":"Karima Sanz KA-A","year":"2023","unstructured":"Sanz KA-A Karima, Parente CE, Ferreras C, Ribes MM, Navarro A, Mestre C, et al. Familial CD45RA\u2013 T cells to treat severe refractory infections in immunocompromised patients. Front Med. 2023;10:1083215. https:\/\/doi.org\/10.3389\/fmed.2023.1083215.","journal-title":"Front Med"},{"key":"2050_CR45","doi-asserted-by":"publisher","first-page":"173","DOI":"10.14776\/piv.2023.30.e18","volume":"30","author":"HJ Chin","year":"2023","unstructured":"Chin HJ, Ryu YH, Kang DY, Park HJ, Hong KT, Choi JY, et al. CD45RA+ depleted lymphocyte infusion for treatment of refractory cytomegalovirus disease in complete DiGeorge syndrome: a case report. Pediatric Infection & Vaccine. 2023;30:173\u20139. https:\/\/doi.org\/10.14776\/piv.2023.30.e18.","journal-title":"Pediatric Infection & Vaccine"},{"key":"2050_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2024.107043","volume":"144","author":"M Zhang","year":"2024","unstructured":"Zhang M, Luo C, Wang J, Zhu H, Luo C, Qin X, et al. TCR\u03b1\u03b2-depleted hematopoietic stem cell transplant and third-party CD45RA+ depleted adoptive cell therapy for treatment of post-transplant parvovirus B19 aplastic crisis. Int J Infect Dis. 2024;144:107043. https:\/\/doi.org\/10.1016\/j.ijid.2024.107043.","journal-title":"Int J Infect Dis"},{"key":"2050_CR47","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.3324\/haematol.2011.059378","volume":"97","author":"B Federmann","year":"2012","unstructured":"Federmann B, Bornhauser M, Meisner C, Kordelas L, Beelen DW, Stuhler G, et al. Haploidentical allogneic hematopoietic cell transplantation in adults using CD3\/CD19 depletion and reduced intensity conditioning: a phase II study. Haematologica. 2012;97:1523\u201331. https:\/\/doi.org\/10.3324\/haematol.2011.059378.","journal-title":"Haematologica"},{"key":"2050_CR48","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.3389\/fimmu.2019.01854","volume":"10","author":"P Zhang","year":"2019","unstructured":"Zhang P, Tey S-K. Adoptive T cell therapy following haploidentical hematopoietic stem cell transplantation. Front Immunol. 2019;10:1854. https:\/\/doi.org\/10.3389\/fimmu.2019.01854.","journal-title":"Front Immunol"},{"key":"2050_CR49","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1556\/030.2021.01620","volume":"68","author":"L Gopcsa","year":"2021","unstructured":"Gopcsa L, Bobek I, Bek\u0151 G, Lakatos B, Moln\u00e1r E, R\u00e9ti M, et al. Common points of therapeutic intervention in COVID-19 and in allogeneic hematopoietic stem cell transplantation associated severe cytokine release syndrome. Acta Microbiol Immunol Hung. 2021;68:240\u201355.","journal-title":"Acta Microbiol Immunol Hung"},{"key":"2050_CR50","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/labmed\/lmac132","volume":"54","author":"AB Morris","year":"2023","unstructured":"Morris AB, Bray R, Gebel HM, Sullivan HC. A primer on chimerism analysis: a straightforward, thorough review. Lab Med. 2023;54:352\u201362.","journal-title":"Lab Med"},{"key":"2050_CR51","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.bbmt.2019.12.220","volume":"26","author":"A Flower","year":"2020","unstructured":"Flower A, Ayello J, Harrison L, Morris E, Sturhahn M, Maryamchik E, et al. The safety and efficacy of targeted virus specific cytotoxic T-lymphocytes (VST) manufactured by the IFN-g Cytokine Capture System (CCS) for the treatment of refractory adenovirus (ADV), cytomegalovirus (CMV), Epstein Barr virus (EBV) and BK virus (BKV) in children, adolescents and young adults (CAYA) after allogeneic hematopoietic stem cell transplantation (Allo-HSCT), solid organ transplantation (SOT), or with primary immunodeficiency (PID) (IND#17449). Biol Blood Marrow Transplant. 2020;26:8\u201374. https:\/\/doi.org\/10.1016\/j.bbmt.2019.12.220.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2050_CR52","doi-asserted-by":"publisher","unstructured":"Arevalo-Romero JA, Chingat\u00e9-L\u00f3pez SM, Camacho BA, Alm\u00e9ciga-D\u00edaz CJ, Ramirez-Segura. Nex-generation treatments: Immunotherapy and advanced therapies for COVID-19. Heliyon. 2024;10: e26423. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e26423.","DOI":"10.1016\/j.heliyon.2024.e26423"},{"key":"2050_CR53","doi-asserted-by":"publisher","unstructured":"Ljungman P, de la Camara R, Mikulska M, Tridello G, Aguado B, Al Zahrani M, Apperley J, Berceanu A, Bofarull RM, Calbacho M, Ciceri F, Lopez-Corral L, Crippa C, Fox ML, Grassi A, Jimenez M-J, Demir SK, Kwon M, Llamas CV, Lorenzo JLL, Mielke S, Orchard K, Porras RP, Vallisa D, Xhaard A, Knelange NS, Cedillo A, Kr\u00f6ger N, Pi\u0148ana JL, Styczynski. COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. Leukemia. 2021;35: 2885\u201394. https:\/\/doi.org\/10.1038\/s41375-021-01302-5.","DOI":"10.1038\/s41375-021-01302-5"},{"key":"2050_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1125824","volume":"14","author":"P Ljungman","year":"2023","unstructured":"Ljungman P, Tridello G, Pi\u0148ana JL, Ciceri F, Sengeloev H, Kulagin A, et al. Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; an infectious disease working party study from the European Society for Blood and Marrow Transplantation registry. Front Immunol. 2023;14:1125824. https:\/\/doi.org\/10.3389\/fimmu.2023.1125824.","journal-title":"Front Immunol"},{"key":"2050_CR55","doi-asserted-by":"publisher","first-page":"e453","DOI":"10.1016\/S1473-3099(23)00815-0","volume":"24","author":"HM Machkovech","year":"2024","unstructured":"Machkovech HM, Hahn AM, Wang JG, Grubaugh ND, Halfmann PJ, Johnson MC, et al. Persistent SARS-CoV-2 infection: significance and implications. Lancet Infect Dis. 2024;24:e453\u201362. https:\/\/doi.org\/10.1016\/S1473-3099(23)00815-0.","journal-title":"Lancet Infect Dis"},{"key":"2050_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinpr.2022.100210","volume":"16","author":"D Hettle","year":"2022","unstructured":"Hettle D, Hutchings S, Muir P, Moran E. Persistent SARS-CoV-2 infection in immunocompromised patients facilitates rapid viral evolution: retrospective cohort study and literature review. Clinical Infection in Practice. 2022;16:100210. https:\/\/doi.org\/10.1016\/j.clinpr.2022.100210.","journal-title":"Clinical Infection in Practice"},{"key":"2050_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51924-3","volume":"15","author":"M Nooruzzaman","year":"2024","unstructured":"Nooruzzaman M, Johnson KEE, Rani R, Finkelsztein EJ, Caserta LC, Kodiyanplakkal RP, et al. Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections. Nat Commun. 2024;15:7999. https:\/\/doi.org\/10.1038\/s41467-024-51924-3.","journal-title":"Nat Commun"},{"key":"2050_CR58","doi-asserted-by":"publisher","DOI":"10.1177\/20499361251314763","volume":"12","author":"AN Siddiqui","year":"2025","unstructured":"Siddiqui AN, Musharaf I, Gulumbe BH. The JN.1 variant of COVID-19: immune evasion, transmissibility, and implications for global health. Ther Adv Infect Dis. 2025;12:20499361251314764. https:\/\/doi.org\/10.1177\/20499361251314763.","journal-title":"Ther Adv Infect Dis"},{"key":"2050_CR59","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00281-024-01031-8","volume":"47","author":"D Nardo","year":"2025","unstructured":"Nardo D, Maddox EG, Riley JL. Cell therapies for viral diseases: a new frontier. Semin Immunopathol. 2025;47:5. https:\/\/doi.org\/10.1007\/s00281-024-01031-8.","journal-title":"Semin Immunopathol"},{"key":"2050_CR60","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1159\/000540961","volume":"52","author":"K Koukoulias","year":"2024","unstructured":"Koukoulias K, Papayanni PG, Leen AM, Vasileiou S. Virus-specific T-cell therapy for the management of viral infections in the immunocompromised. Transfus Med Hemother. 2024;52:5\u201326. https:\/\/doi.org\/10.1159\/000540961.","journal-title":"Transfus Med Hemother"},{"key":"2050_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116066","volume":"222","author":"Y Chen","year":"2024","unstructured":"Chen Y, Liu C, Fang Y, Chen W, Qiu J, Zhu M, et al. Developing CAR-immune cell therapy against SARS-CoV-2: current status, challenges and prospects. Biochem Pharmacol. 2024;222:116066. https:\/\/doi.org\/10.1016\/j.bcp.2024.116066.","journal-title":"Biochem Pharmacol"},{"key":"2050_CR62","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cmet.2019.09.010","volume":"31","author":"C Campbell","year":"2020","unstructured":"Campbell C, Rudensky A. Roles of regulatory T cells in tissue pathophysiology and metabolism. Cell Metab. 2020;31:18\u201325. https:\/\/doi.org\/10.1016\/j.cmet.2019.09.010.","journal-title":"Cell Metab"},{"key":"2050_CR63","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1093\/infdis\/jiy478","volume":"219","author":"H Loy","year":"2019","unstructured":"Loy H, Kuok DIT, Hui KPY, Choi MHL, Yuen W, Nicholls JM, et al. Therapeutic implications of human umbilical cord mesenchymal stromal cells in attenuating influenza A(H5N1) virus\u2013associated acute lung injury. J Infect Dis. 2019;219:186\u201396. https:\/\/doi.org\/10.1093\/infdis\/jiy478.","journal-title":"J Infect Dis"},{"key":"2050_CR64","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.1000","volume":"11","author":"C Yan","year":"2023","unstructured":"Yan C, Hu M, Dai R. Safety and efficacy of mesenchymal stem cells in COVID-19 patients: a systematic review and meta-analysis. Immunity Inflamm Dis. 2023;11:e1000. https:\/\/doi.org\/10.1002\/iid3.1000.","journal-title":"Immunity Inflamm Dis"},{"key":"2050_CR65","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1111\/ajt.16927","volume":"22","author":"K Martits-Chalangari","year":"2022","unstructured":"Martits-Chalangari K, Spak CW, Askar M, Killian A, Fisher TL, Atillasoy E, et al. ALVR109, an off-the-shelf partially HLA matched SARS-CoV-2-specific T cell therapy, to treat refractory severe COVID-19 pneumonia in a heart transplant patient: case report. Am J Transplant. 2022;22:1261\u20135. https:\/\/doi.org\/10.1111\/ajt.16927.","journal-title":"Am J Transplant"},{"key":"2050_CR66","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.3324\/haematol.2022.281946","volume":"108","author":"S Vasileiou","year":"2022","unstructured":"Vasileiou S, Hill L, Kuvalekar M, Workineh AG, Watanabe A, Velazquez Y, et al. Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high risk patients. Haematologica. 2022;108:1840\u201350. https:\/\/doi.org\/10.3324\/haematol.2022.281946.","journal-title":"Haematologica"},{"key":"2050_CR67","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/cid\/ciad233","volume":"77","author":"G Haidar","year":"2023","unstructured":"Haidar G, Jacobs JL, Hughes Kramer K, Naqvi A, Heaps A, Parikh U, et al. Therapy with allogeneic SARS-CoV-2-specific T-cells for persistent COVID-19 in immunocompromised patients. Clin Infect Dis. 2023;77:696\u2013702. https:\/\/doi.org\/10.1093\/cid\/ciad233.","journal-title":"Clin Infect Dis"},{"key":"2050_CR68","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1038\/s41591-023-02480-8","volume":"29","author":"A Papadopoulou","year":"2023","unstructured":"Papadopoulou A, Karavalakis G, Papadopoulou E, Xochelli A, Bousiou Z, Vogiatzoglou A, et al. SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1\/2 trial. Nat Med. 2023;29:2019\u201329. https:\/\/doi.org\/10.1038\/s41591-023-02480-8.","journal-title":"Nat Med"},{"key":"2050_CR69","doi-asserted-by":"publisher","unstructured":"Lee R, Kim N, Kim W-B, Im K-I, Nho D, Cho S-Y, Park C, Beck KS, Lee GH, Lee I, Cho S-G, Lee D-G. Effectiveness and safety of autologous virus-specific T cell therapy for persistent COVID-19 in people with immunocompromise: A Clinical Trial Study. Clin Infect Dis. 2025; ciaf302. https:\/\/doi.org\/10.1093\/cid\/ciaf302.","DOI":"10.1093\/cid\/ciaf302"},{"key":"2050_CR70","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1182\/bloodadvances.2024013344","volume":"8","author":"D Grosso","year":"2024","unstructured":"Grosso D, Wagner JL, O\u2019Connor A, Keck K, Huang Y, Wang Z-X, et al. Safety and feasibility of third-party cytotoxic T lymphocytes for high-risk patients with COVID-19. Blood Adv. 2024;8:4113\u201324. https:\/\/doi.org\/10.1182\/bloodadvances.2024013344.","journal-title":"Blood Adv"},{"key":"2050_CR71","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jcyt.2023.10.002","volume":"26","author":"C Ferreras","year":"2024","unstructured":"Ferreras C, Hern\u00e1ndez-Blanco C, Mart\u00edn-Quir\u00f3s A, Al-Akioui-Sanz K, Mora-Rillo M, Ib\u00e1\u00f1ez F, et al. Results of phase 2 randomized multi-center study to evaluate the safety and efficacy of infusion of memory T cells as adoptive therapy in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia and\/or lymphopenia (RELEASE NCT04578210). Cytotherapy. 2024;26:25\u201335. https:\/\/doi.org\/10.1016\/j.jcyt.2023.10.002.","journal-title":"Cytotherapy"},{"key":"2050_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s13027-025-00654-2","volume":"20","author":"C Li","year":"2025","unstructured":"Li C, Xu D, Lu L, Peng S, Zhao H, Zeng C, et al. Clinical impact of concurrent autologous adoptive T cells immunotherapy in acitve COVID-19 infected cancer patients for chmeotherapy. Infect Agent Cancer. 2025;20:23.","journal-title":"Infect Agent Cancer"},{"key":"2050_CR73","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1038\/s41409-021-01232-x","volume":"56","author":"M Dunaikina","year":"2021","unstructured":"Dunaikina M, Zhekhovtsova Z, Shelikhova L, Glushkova S, Nikolaev R, Blagov S, et al. Safety and efficacy of the low-dose memory (CD45RA-depleted) donor lymphocyte infusion in recipients of \u03b1\u03b2 T cell-depleted haploidentical grafts: results of a prospective randomized trial in high-risk childhood leukemia. Bone Marrow Transplant. 2021;56:1614\u201324. https:\/\/doi.org\/10.1038\/s41409-021-01232-x.","journal-title":"Bone Marrow Transplant"},{"key":"2050_CR74","doi-asserted-by":"publisher","first-page":"478.e1","DOI":"10.1016\/j.jtct.2021.03.010","volume":"27","author":"L Castagna","year":"2021","unstructured":"Castagna L, Valli V, Timofeeva I, Capizzuto R, Bramanti S, Mariotti J, et al. Feasibility and efficacy of CD45RA+ depleted donor lymphocytes infusion after haploidentical transplantation with post-transplantation cyclophosphamide in patients with hematological malignancies. Transplantation and Cellular Therapy. 2021;27:478.e1-478.e5. https:\/\/doi.org\/10.1016\/j.jtct.2021.03.010.","journal-title":"Transplantation and Cellular Therapy"},{"key":"2050_CR75","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/s41592-021-01201-8","volume":"18","author":"JA Pai","year":"2021","unstructured":"Pai JA. High-throughput and single-cell T cell receptor sequencing technologies. Nat Methods. 2021;18:881\u201392. https:\/\/doi.org\/10.1038\/s41592-021-01201-8.","journal-title":"Nat Methods"},{"key":"2050_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2025.102783","volume":"109","author":"J Wu","year":"2025","unstructured":"Wu J, Zhang L, Zhao Z, Liu Y, Li Z, Feng X, et al. Advancing T-cell immunotherapy for cellular senescence and disease: mechanisms, challenges, and clinical prospects. Ageing Res Rev. 2025;109:102783. https:\/\/doi.org\/10.1016\/j.arr.2025.102783.","journal-title":"Ageing Res Rev"},{"key":"2050_CR77","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3390\/cells14070499","volume":"14","author":"S Wang","year":"2025","unstructured":"Wang S, Huo T, Lu M, Zhao Y, Zhang J, He W, et al. Recent advances in aging and immunosenescence: mechanisms and therapeutic strategies. Cells. 2025;14:499. https:\/\/doi.org\/10.3390\/cells14070499.","journal-title":"Cells"},{"key":"2050_CR78","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/0014-4827(65)90211-9","volume":"37","author":"L Hayflick","year":"1965","unstructured":"Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res. 1965;37:614\u201336. https:\/\/doi.org\/10.1016\/0014-4827(65)90211-9.","journal-title":"Exp Cell Res"},{"key":"2050_CR79","doi-asserted-by":"publisher","first-page":"1360109","DOI":"10.3389\/fimmu.2024.1360109","volume":"15","author":"K Matveeva","year":"2024","unstructured":"Matveeva K, Vasilieva M, Minskaia E, Rybtsov S, Shevyrev D. T-cell immunity against senescence: potential role and perspectives. Front Immunol. 2024;15:1360109. https:\/\/doi.org\/10.3389\/fimmu.2024.1360109.","journal-title":"Front Immunol"},{"key":"2050_CR80","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1158\/2159-8290.CD-22-0523","volume":"13","author":"I Marin","year":"2023","unstructured":"Marin I, Boix O, Garcia-Garijo A, Sirois I, Caballe A, Zarzuela E, et al. Cellular senescence is immunogenic and promotes antitumor immunity. Cancer Discov. 2023;13:410\u201331. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0523.","journal-title":"Cancer Discov"},{"key":"2050_CR81","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000036045","volume":"102","author":"Z Fu","year":"2023","unstructured":"Fu Z, Xu H, Yue L, Zheng W, Pan L, Gao F, et al. Immunosenescence and cancer: opportunities and challenges. Medicine. 2023;102:e36045. https:\/\/doi.org\/10.1097\/MD.0000000000036045.","journal-title":"Medicine"},{"key":"2050_CR82","doi-asserted-by":"publisher","first-page":"1565278","DOI":"10.3389\/fimmu.2025.1565278","volume":"16","author":"M Gergues","year":"2025","unstructured":"Gergues M, Bari R, Koppisetti S, Gosiewska A, Kang L, Hariri RJ. Senescence, NK cells, and cancer: navigating the crossroads of aging and disease. Front Immunol. 2025;16:1565278. https:\/\/doi.org\/10.3389\/fimmu.2025.1565278.","journal-title":"Front Immunol"},{"key":"2050_CR83","doi-asserted-by":"publisher","DOI":"10.1186\/s12979-023-00406-z","volume":"21","author":"JM Lord","year":"2024","unstructured":"Lord JM, Veenith T, Sullivan J, Sharma-Oates A, Richter AG, Greening NJ, et al. Accelerated immune ageing is associated with COVID-19 disease severity. Immun Ageing. 2024;21:6. https:\/\/doi.org\/10.1186\/s12979-023-00406-z.","journal-title":"Immun Ageing"},{"key":"2050_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2023.101755","volume":"74","author":"JJ Baechle","year":"2023","unstructured":"Baechle JJ, Chen N, Makhijani P, Winer S, Furman D, Winer DA. Chronic inflammation and the hallmarks of aging. Mol Metab. 2023;74:101755. https:\/\/doi.org\/10.1016\/j.molmet.2023.101755.","journal-title":"Mol Metab"},{"key":"2050_CR85","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/joim.13141","volume":"288","author":"JL Kirkland","year":"2020","unstructured":"Kirkland JL, Tchkonia T. Senolytic drugs: from discovery to translation. J Intern Med. 2020;288:518\u201336. https:\/\/doi.org\/10.1111\/joim.13141.","journal-title":"J Intern Med"},{"key":"2050_CR86","doi-asserted-by":"publisher","DOI":"10.1093\/oxfimm\/iqad004","volume":"4","author":"PY Du","year":"2023","unstructured":"Du PY, Gandhi A, Bawa M, Gromala J. The ageing immune system as a potential target of senolytics. Oxf Open Immunol. 2023;4:iqad004. https:\/\/doi.org\/10.1093\/oxfimm\/iqad004.","journal-title":"Oxf Open Immunol"},{"key":"2050_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41514-024-00138-4","volume":"10","author":"V Lelarge","year":"2024","unstructured":"Lelarge V, Capelle R, Oger F, Mathieu T, Le Calv\u00e9 B. Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients\u2019 treatment. NPJ Aging. 2024;10:12. https:\/\/doi.org\/10.1038\/s41514-024-00138-4.","journal-title":"NPJ Aging"},{"key":"2050_CR88","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41586-020-2403-9","volume":"583","author":"C Amor","year":"2020","unstructured":"Amor C, Feucht J, Leibold J, Ho YJ, Zhu C, Alonso-Curbelo D, et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature. 2020;583:127\u201332. https:\/\/doi.org\/10.1038\/s41586-020-2403-9.","journal-title":"Nature"},{"key":"2050_CR89","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.add1951","volume":"15","author":"D Yang","year":"2023","unstructured":"Yang D, Sun B, Li S, Wei W, Liu X, Cui X, et al. NKG2D-CAR T cells eliminate senescent cells in aged mice and nonhuman primates. Sci Transl Med. 2023;15:eadd1951. https:\/\/doi.org\/10.1126\/scitranslmed.add1951.","journal-title":"Sci Transl Med"},{"key":"2050_CR90","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-019-1546-z","volume":"573","author":"H Aghajanian","year":"2019","unstructured":"Aghajanian H, Kimura T, Rurik JG, Hancock AS, Leibowitz MS, Li L, et al. Targeting cardiac fibrosis with engineered T cells. Nature. 2019;573:430\u20133. https:\/\/doi.org\/10.1038\/s41586-019-1546-z.","journal-title":"Nature"},{"key":"2050_CR91","doi-asserted-by":"publisher","DOI":"10.20517\/jca.2024.06","volume":"4","author":"P Zhai","year":"2024","unstructured":"Zhai P, Sadoshima J. Cardiomyocyte senescence and the potential therapeutic role of senolytics in the heart. J Cardiovasc Aging. 2024;4:18. https:\/\/doi.org\/10.20517\/jca.2024.06.","journal-title":"J Cardiovasc Aging"},{"key":"2050_CR92","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/ana.26375","volume":"92","author":"DR Beers","year":"2022","unstructured":"Beers DR, Thonhoff JR, Faridar A, Thome AD, Zhao W, Wen S, et al. Tregs attenuate peripheral oxidative stress and acute phase proteins in ALS. Ann Neurol. 2022;92:195\u2013200. https:\/\/doi.org\/10.1002\/ana.26375.","journal-title":"Ann Neurol"},{"key":"2050_CR93","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14548","volume":"21","author":"W Elyaman","year":"2025","unstructured":"Elyaman W, Stern L, Jiang N, Dressman D, Bradley P, Klatzmann D, et al. Exploring the role of T cells in Alzheimer\u2019s and other neurodegenerative diseases: emerging therapeutic insights from the T cells in the brain symposium. Alzheimer\u2019s & Dementia. 2025;21:e14548. https:\/\/doi.org\/10.1002\/alz.14548.","journal-title":"Alzheimer's & Dementia"},{"key":"2050_CR94","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12979-024-00451-2","volume":"21","author":"X Deng","year":"2024","unstructured":"Deng X, Terunuma H. Adoptive NK cell therapy: a potential revolutionary approach in longevity therapeutics. Immun Ageing. 2024;21:43. https:\/\/doi.org\/10.1186\/s12979-024-00451-2.","journal-title":"Immun Ageing"},{"key":"2050_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrep.2022.101380","volume":"32","author":"N Chelyapov","year":"2022","unstructured":"Chelyapov N, Nguyen TT, Gonzalez R. Autologous NK cells propagated and activated ex vivo decrease senescence markers in human PBMCs. Biochem Biophys Rep. 2022;32:101380. https:\/\/doi.org\/10.1016\/j.bbrep.2022.101380.","journal-title":"Biochem Biophys Rep"},{"key":"2050_CR96","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41556-023-01097-w","volume":"25","author":"F di d'Adda Fagagna","year":"2023","unstructured":"di d\u2019Adda Fagagna F. SARS-CoV-2 causes DNA damage, cellular senescence andinflammation. Nat Cell Biol. 2023;25:526\u20137. https:\/\/doi.org\/10.1038\/s41556-023-01097-w.","journal-title":"Nat Cell Biol"},{"key":"2050_CR97","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf430","author":"RM Bruno","year":"2025","unstructured":"Bruno RM, Badhwar S, Abid L, Agharazii M, Anastasio F, Bellien J, et al. Accelerated vascular ageing after COVID-19 infection: the CARTESIAN study. Eur Heart J. 2025. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf430.","journal-title":"Eur Heart J"},{"key":"2050_CR98","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25158056","volume":"25","author":"M Campisi","year":"2024","unstructured":"Campisi M, Cannella L, Bordin A, Moretto A, Scapellato ML, Mason P, et al. Revealing the hidden impacts: insights into biological aging and long-term effects in pauci- and asymptomatic COVID-19 healthcare workers. Int J Mol Sci. 2024;25:8056. https:\/\/doi.org\/10.3390\/ijms25158056.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2050_CR99","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1182\/blood-2021-153133","volume":"138","author":"S Morin","year":"2021","unstructured":"Morin S, Pradier A, Giannotti F, Mamez A-C, Vu-Cantero D-L, Fabra-Urdiola M, et al. Expansion of phenotypically senescent CD57+ CD8 T cells is associated with impaired immunocompetence after allogeneic hematopoietic stem cell transplantation. Blood. 2021;138(1):1807. https:\/\/doi.org\/10.1182\/blood-2021-153133.","journal-title":"Blood"},{"key":"2050_CR100","doi-asserted-by":"publisher","unstructured":"Delval L, Hantute-Ghesquier A,\u00a0Sencio V, Flaman JM, Robil C, Angulo FS, Lipskaia L, \u00c7obano\u011flu O,\u00a0Lacoste A-S, Machelart A, Danneels A, Corbin M, Deruyter L, Heumel S, Idziorek T, S\u00e9ron K, Sauve K, Bongiovanni A, Pr\u00e9vot V, Wolowczuk I, Belouzard S, Saliou J-M, Gosset P, Bernard D, Rouill\u00e9 Y, Adnot S, Duterque-Coquillaud M, Trottein F. Removal of senescent cells reduces the viral load and attenuates pulmonary and systemic inflammation in SARS-CoV-2-infected, aged hamsters.Nat Aging. 2023;3: 829\u2013845. https:\/\/doi.org\/10.1038\/s43587-023-00442-w.","DOI":"10.1038\/s43587-023-00442-w"},{"key":"2050_CR101","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12103539","volume":"12","author":"E Vazquez-Alejo","year":"2023","unstructured":"Vazquez-Alejo E, Espinar-Buitrago MS, Genebat M, Calder\u00f3n M, P\u00e9rez-Cabeza G, Magro-Lopez E, et al. Persistent exhausted T-cell immunity after severe COVID-19: 6-month evaluation in a prospective observational study. J Clin Med. 2023;12:3539. https:\/\/doi.org\/10.3390\/jcm12103539.","journal-title":"J Clin Med"},{"key":"2050_CR102","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3390\/biologics2030013","volume":"2","author":"VP Chavda","year":"2022","unstructured":"Chavda VP, Chhabria MT, Apostolopoulos V. Aged population and immunocompromised patients: impact on SARS-CoV-2 variants and treatment outcomes. Biologics. 2022;2:165\u201370. https:\/\/doi.org\/10.3390\/biologics2030013.","journal-title":"Biologics"},{"key":"2050_CR103","doi-asserted-by":"publisher","DOI":"10.3390\/ijms251910512","volume":"25","author":"KI Im","year":"2024","unstructured":"Im KI, Kim N, Lee J, Oh UH, Lee HW, Lee DG, et al. SARS-CoV-2-specific T-cell as a potent therapeutic strategy against immune evasion of emerging COVID-19 variants. Int J Mol Sci. 2024;25:10512. https:\/\/doi.org\/10.3390\/ijms251910512.","journal-title":"Int J Mol Sci"}],"container-title":["GeroScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-025-02050-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11357-025-02050-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-025-02050-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T10:08:57Z","timestamp":1783764537000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11357-025-02050-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":103,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["2050"],"URL":"https:\/\/doi.org\/10.1007\/s11357-025-02050-5","relation":{},"ISSN":["2509-2723"],"issn-type":[{"value":"2509-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"assertion":[{"value":"27 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}